

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-4 (Cancelled).

5 (Currently amended). The use ~~according to anyone of the preceding claims~~ method according to claim 11, wherein the VEGF inhibitor is selected from the group consisting of DMPX, an A2-antagonist 7-(betahydroxyethyl)theophylline, 8-phenyltheophylline, the adenosine A2 receptor antagonist CSC, theobromine, an antagonistic VEGF variant, sFLT-1, Tranilast, 8-(3-oxo-4,5,6-trihydroxy-3h-xanthen-9-yl)-1-naphthoic acid, suramin and platelet factor-4.

6 (Withdrawn). A pharmaceutical composition for reversibly inhibiting endothelial cell proliferation comprising leptin or a leptin homologue or derivative optionally together with an inhibitor of VEGF action or of VEGF synthesis and/or an inhibitor of angiogenesis.

7 (Withdrawn). A pharmaceutical composition according to claim 6 for modulating angiogenic processes.

8 (Withdrawn). A pharmaceutical composition according to claim 7 for inhibiting angiogenesis.

9 (Currently amended). A method for reversibly inhibiting endothelial cell proliferation in mammals, comprising

Appln. No. 10/070,295

Amd. dated December 15, 2005

Reply to Office Action of November 15, 2005

administering to a subject a pharmaceutical composition, which comprises leptin, or a homologue or derivative thereof, and optionally, an inhibitor of angiogenesis, ~~according to any one of claims 6 to 9~~ in a suitable dosage form and by a suitable route of administration.

10(Withdrawn). A mixture comprising leptin and a VEGF inhibitor.

11(New). The method of claim 9, wherein the inhibitor of angiogenesis is a VEGF inhibitor.